|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
LHGDN |
Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.
|
16502590 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.
|
16537803 |
2006 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Recently, several groups identified a recurrent somatic point mutation constitutively activating the hematopoietic growth factor receptor-associated JAK2 tyrosine kinase in diverse chronic myeloid disorders - most commonly classic myeloproliferative disorders (MPD), especially polycythemia vera.
|
16598306 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
DNA from 161 samples was isolated from peripheral blood granulocytes and formalin-fixed bone marrow clot sections in patients with CMPDs and without myeloproliferative disorders previously genotyped for the JAK2 V617F (G-->T) mutation, which included 114 wild types (GG) and 47 mutants (GT and TT).
|
16627272 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The V617F activating point mutation in Jak2 has recently been associated with myeloproliferative disorders.
|
16632470 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Questions remain regarding the exact contribution of JAK2(V617F) in other myeloproliferative disorders.
|
16670266 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recent information regarding disease pathogenesis, including a contribution to the myeloproliferative disorder phenotype by a gain-of-function JAK2 mutation (JAK2(V617F)), has revived the prospect of targeted therapeutics as well as molecular monitoring of treatment response.
|
16675707 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.
|
16675710 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
|
16810610 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The main conclusion is that JAK2 V617F is a 100% specific clue to a new distinct clonal myeloproliferative disorder.
|
16810614 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A point mutation in the JAK2 gene, a member of the tyrosine kinase family, was recently identified and shown to be associated with several myeloproliferative disorders.
|
16825505 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
JAK2(V617F) was identified in patients previously diagnosed with a myeloproliferative disorder or acute myeloid leukemia transformed from myeloproliferative disorder, whereas a wild-type genotype was identified in patients with reactive conditions or de novo acute myeloid leukemia.
|
16831057 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.
|
16873677 |
2006 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
We review evidence that the pseudokinase STRAD controls the function of the tumour suppressor kinase LKB1 and that a single amino acid substitution within the pseudokinase domain of the tyrosine kinase JAK2 leads to several malignant myeloproliferative disorders.
|
16879967 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The acquired mutation Val617Phe in the tyrosine kinase JAK2 was recently identified in most but not all patients with classical myeloproliferative disorders.
|
16885051 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders.
|
16886215 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.
|
16901656 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We aimed to determine the relative sensitivity of four separate molecular assays used to detect the presence of the JAK2 V617F mutation in peripheral blood from patients with essential thrombocythaemia and related myeloproliferative disorders.
|
16916724 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recently, the JAK2(V617F) mutation was found in patients with myeloproliferative disorders (MPDs), including most with polycythemia vera (PV).
|
16946305 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The authors studied the biologic significance of the JAK2 (V617F) mutation in familial myeloproliferative disorders.
|
16998940 |
2006 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
We therefore believe that the assay will contribute to early diagnosis of myeloproliferative disorders and to disease management, especially when JAK2-specific inhibitors have become available for therapeutic use.
|
17006961 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A common point mutation in the JAK2 tyrosine kinase leads to constitutive hematopoietic growth factor receptor signaling and was recently described in many patients with myeloproliferative disorders (MPDs).
|
17013813 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
|
17022694 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.
|
17045648 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.
|
17045648 |
2007 |